Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC009496 | Panoply™ Human MGST1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC009496 | Panoply™ Human MGST1 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09935Z | Human MGST1 adenoviral particles | Inquiry |
| LV18216L | human MGST1 (NM_020300) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH341719 | shRNA set against Human MGST1 (NM_020300.4) | Inquiry |
| SHW002812 | shRNA set against Chicken MGST1 (NM_001135550) | Inquiry |
| SHH188993 | shRNA set against Mouse Mgst1(NM_019946.4) | Inquiry |
| SHH189029 | shRNA set against Rat Mgst1(NM_134349.3) | Inquiry |
| SHH341723 | shRNA set against Mouse MGST1 (NM_019946.4) | Inquiry |
| SHH341727 | shRNA set against Rat MGST1 (NM_134349.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR014148 | Rat Mgst1 cDNA Clone(NM_134349.3) | Inquiry |
| MiUTR1M-07104 | MGST1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-03913 | MGST1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-00905 | MGST1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-00906 | MGST1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-00907 | MGST1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-00908 | MGST1 miRNA 3'UTR clone | Inquiry |
| CDCB164287 | Chicken MGST1 ORF Clone (NM_001135550) | Inquiry |
| CDCB193131 | Rabbit MGST1 ORF clone (XM_002712624.2) | Inquiry |
| CDCH389196 | Mouse MGST1 ORF clone(NM_019946.4) | Inquiry |
| CDCR381033 | Rat Mgst1 ORF Clone(NM_134349.3) | Inquiry |
Microsomal glutathione S-transferase (mGST) includes mGST-I, mGST-II, mGST-III, prostaglandin E synthase (PEG synthase), leukotriene C4 synthase (LTC4 synthase), 5-lipoxygenase activating protein (FLAP), etc. The mGST supergene family plays a very important role in the metabolism of exogenous and endogenous compounds. Most of the substrates are fat-soluble electrophilic compounds, which are easier to bind to the substrate than cGST. mGST and cytochrome P-450 enzyme (CYP450) are located on the endoplasmic reticulum membrane. Exogenous compounds catalyzed by P-450 oxidase are metabolized here and detoxified directly under the action of mGST. cGST requires the electrophilic group formed in the microsomes to pass through the microsomal membrane to the cytosol to complete the detoxification process.
mGST is widely distributed in the liver, kidney, lung, small intestine, adrenal gland, testis, heart, spleen and other tissues and organs. Among them, the liver is the most abundant, and several subtypes have been purified from human liver cell microsomes. The mGTI is the main cell in the cell mGST. Rat liver mGST content accounts for about 3.1% of microsomal protein, 4.8% of mitochondrial outer membrane protein. The concentration of mGST in endoplasmic reticulum is about 1 mmol·L-1. The amount of mGST present in the plasma membrane tubules and sinusoidal tubules of the hepatocytes was 2% and 0.5% to 1%, respectively. Mammalian liver mGST concentrations are approximately similar and are not increased by induction of drug enzyme inducers such as phenobarbital. However, the content of mGST in the metabolic tissues and organs such as human fetal adrenal glands is 373% in the liver, while the content of mGST in the adult adrenal glands is only 20% in the liver, suggesting that mGST varies in human development and is closely related to metabolic capacity.
Figure 1. Different classes of glutathione S-transferase. (Smita, K., et al. 2018)
mGST and Drug Metabolism
Many drugs can cause lipid peroxidation. mGST-I functions as GSH-Px and acts as an anti-lipid peroxidation. ctivation of mGST-I may be an effective response to the toxic effects of the body on oxidative stress. The drug containing thiourea structure can transiently activate rat mGST after being metabolized by monooxygenase FMO and CYP450 enzyme, predicting that rat liver mGST can be used as a biological test system for evaluating the relationship between structure and alkylation of thiourea-containing structural compounds in vitro. Prednisolone can increase lipid peroxidation and membrane fluidity of the liver membrane, and reduce liver-binding function mediated by mGST and cGST in rats, thereby increasing sensitivity to toxicants.
The mGST present on the liver microsomal membrane is different from cGST in terms of substrate properties, relative molecular mass, gene arrangement and immunology. Most of the hydrophobic drugs produced by the CYP450 enzyme may remain on the microsomes due to their certain lipophilicity and do not diffuse into the cytosol, resulting in ineffective contact with cGST. These drugs are first activated by phase I metabolic enzymes (such as the CYP450 enzyme) and are primarily inactivated by phase II metabolic enzymes (such as the GST enzyme). Norepinephrine activation mGST-I may be a subsequent reaction based on the cytochrome P-450-dependent monooxygenase system to oxidize norepinephrine to a semi-orthophenylene. Moreover, the antineoplastic alkylating agent BCNU is catalyzed by mGST and cytochrome P-450 monooxygenase to catalyze the denitroation. The cytotoxic reagent, other phenylpropionate, chlorambucil, and carbaryl were inactivated by mGST.
References: